GLP-1 and Sleep Apnea: What the Research Says About Ozempic and OSA

How Weight Affects Sleep Apnea

Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses or narrows during sleep, causing brief pauses in breathing. These interruptions are measured by an index called the apnea-hypopnea index (AHI), or the number of breathing events per hour. They can range from mild to severe and are linked to increased risk of cardiovascular disease, high blood pressure, and daytime fatigue.

Excess body weight is one of the strongest risk factors for OSA. Fat deposits around and within the tissues of the upper airway — particularly around the tongue, soft palate, and throat — reduce the diameter of the airway and make it more likely to collapse during sleep.¹ Research published in the American Journal of Respiratory and Critical Care Medicine found that tongue fat reduction was the primary upper-airway mechanism by which weight loss improved AHI, meaning that losing fat in the tongue and throat may be just as important as overall body weight reduction.²

Studies consistently show that even moderate weight loss can produce meaningful reductions in sleep apnea severity. Research indicates that a 10% reduction in body weight may reduce AHI by approximately 26%, and greater weight loss correlates with even larger reductions.³ You can learn more about recognizing sleep apnea symptoms in our related article on sleep apnea symptoms. Beyond local airway fat changes, abdominal fat loss increases lung volume, which in turn helps keep the throat open during sleep.

What Research Shows About GLP-1 and Sleep Apnea

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that include semaglutide (sold under brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). They were originally developed to manage type 2 diabetes but have since shown significant weight loss benefits, prompting researchers to examine their effects on obesity-related conditions like semaglutide OSA.

The most significant evidence to date comes from the SURMOUNT-OSA trials, two large Phase 3 randomized controlled trials published in the New England Journal of Medicine in 2024. These trials enrolled 469 adults with moderate-to-severe OSA and obesity, assigning them to either tirzepatide or placebo for 52 weeks. In the first trial (patients not using CPAP), tirzepatide reduced AHI by an average of 25.3 events per hour compared to just 5.3 events per hour with placebo — a reduction of up to 63%.⁴ Both trials met all primary and key secondary endpoints.

A 2025 systematic review and meta-analysis published on PubMed found that GLP-1 RAs were superior to placebo in reducing AHI in patients with OSA and obesity, with additional benefits including reduced body weight, lower blood pressure, and improved cardiometabolic risk markers.⁵ Notably, many participants in these trials saw their OSA severity downgraded from moderate-to-severe to mild, and some experienced remission of OSA entirely.

Beyond Weight Loss: Direct Effects on Sleep

While weight loss is clearly a major driver of GLP-1 benefit in OSA, researchers are investigating whether these medications may have effects on the airway that go beyond fat loss alone. GLP-1 receptors are expressed in lung tissue, airway smooth muscle cells, and airway epithelial cells, suggesting the medications may act locally on the respiratory system.⁶

Research published in the National Library of Medicine shows that GLP-1 receptor activation triggers anti-inflammatory pathways in the airway, reducing the release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.⁶ Chronic airway inflammation may worsen OSA by causing tissue swelling and increasing airway resistance, so these anti-inflammatory effects may be relevant.

There is also early evidence suggesting that GLP-1 agonists may relax airway smooth muscle through signaling pathways involving cyclic AMP (cAMP), potentially improving upper airway muscle tone and reducing collapsibility during sleep. However, researchers note that most of the improvement seen in clinical trials appears attributable to weight loss, and direct airway effects remain an area of active investigation rather than established fact.

The Sleep Apnea-PCOS Connection

Women with polycystic ovary syndrome (PCOS) face a significantly elevated risk of developing OSA. Research suggests women with PCOS may be 2 to 30 times more likely to have OSA compared to women without the condition, depending on the population studied and the presence of other factors like obesity.⁷ A large population-based cohort study found that women with PCOS had a 2.26-fold increased risk of developing OSA even after adjusting for body weight, suggesting the hormonal environment of PCOS itself plays a role.⁸

Despite this elevated risk, OSA is frequently underdiagnosed in women with PCOS. Women with OSA often present with atypical symptoms — such as fatigue, mood disturbances, and insomnia — rather than the loud snoring more commonly associated with OSA in men. As a result, OSA may be missed or attributed to other aspects of PCOS.

Because GLP-1 receptor agonists are used in the management of insulin resistance and weight in PCOS, they may offer the benefit of addressing both conditions simultaneously. You may want to discuss sleep screening with your doctor if you have PCOS and experience unexplained fatigue, poor sleep quality, or morning headaches.

Can GLP-1 Replace CPAP?

CPAP (continuous positive airway pressure) therapy remains the first-line, gold-standard treatment for moderate-to-severe OSA. It works by delivering a steady stream of pressurized air through a mask to keep the airway open during sleep. While GLP-1 medications have shown impressive results in reducing OSA severity, researchers and clinicians are clear that they are not a replacement for CPAP in those with significant disease.

The SURMOUNT-OSA trials included a cohort of patients already on CPAP therapy. In that group, tirzepatide also produced meaningful AHI reductions — suggesting GLP-1 RAs may serve as an effective adjunct treatment alongside CPAP, helping improve outcomes and potentially reduce the CPAP pressure settings needed over time.⁴

For individuals with mild OSA who achieve substantial ozempic sleep apnea improvement or weight loss, a reduction in OSA severity to the point where CPAP is no longer required is a realistic possibility — but this determination should only be made through repeat sleep testing (polysomnography) and in consultation with a sleep specialist. Stopping CPAP without retesting could leave ongoing breathing disruptions undetected and untreated.

What to Discuss With Your Sleep Doctor

If you are taking or considering a GLP-1 receptor agonist and also have OSA, or suspect you may have OSA, there are several things worth discussing with your healthcare provider:

• Baseline sleep testing: If you have not had a formal sleep study, ask whether one is appropriate given your symptoms and risk factors. GLP-1 medications will not replace the need for an accurate diagnosis.

• AHI retesting after weight loss: Your sleep doctor may recommend a follow-up sleep study after you have achieved stable weight loss, typically after 6 to 12 months of treatment.

• CPAP adjustments: If you are already on CPAP and losing weight, you may notice that your current pressure settings feel too high. Discuss with your provider whether adjustment is warranted.

• GLP-1 as adjunct therapy: If you have obesity-related OSA, you may want to ask whether GLP-1 medications could be part of a broader management plan alongside CPAP and lifestyle changes.

• PCOS screening: If you are a woman with PCOS who has not been screened for OSA, this conversation is particularly worthwhile given the elevated risk.

When to See a Doctor

You should seek medical evaluation if you experience any of the following, which may indicate obstructive sleep apnea or another sleep disorder:

• Loud snoring, gasping, or choking during sleep (often reported by a bed partner)

• Waking up with a dry mouth, sore throat, or morning headaches

• Excessive daytime sleepiness that interferes with daily activities

• Difficulty concentrating or memory problems

• Witnessed pauses in breathing during sleep

• Frequent nighttime urination

If you are currently on a GLP-1 medication and believe your sleep has changed, this is also worth discussing with your doctor. Changes in weight can alter sleep patterns in complex ways, and monitoring is important.

Conclusion

Research suggests that GLP-1 receptor agonists like semaglutide and tirzepatide can significantly improve OSA severity, primarily through substantial weight loss that reduces fat deposits around the upper airway. The SURMOUNT-OSA trials represent some of the strongest evidence to date, showing AHI reductions of up to 63% with tirzepatide compared to placebo. While emerging science points to possible direct airway and anti-inflammatory effects, these are still being studied. GLP-1 medications are not a replacement for CPAP in moderate-to-severe OSA, but they may serve as a valuable part of a comprehensive treatment approach. Always work with your healthcare team — including your sleep specialist — before making changes to your sleep apnea treatment.

References

1. Schwartz AR, Patil SP, Laffan AM, et al. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc. 2008;5(2):185-192. https://pmc.ncbi.nlm.nih.gov/articles/PMC2645258/

2. Pahkala R, Seppa J, et al. Effect of weight loss on upper airway anatomy and the apnea-hypopnea index: the importance of tongue fat. Am J Respir Crit Care Med. 2020;201(6):718-727. https://pubmed.ncbi.nlm.nih.gov/31918559/

3. Sleep Foundation. Weight loss and sleep apnea. https://www.sleepfoundation.org/sleep-apnea/weight-loss-and-sleep-apnea

4. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1574-1585. https://www.nejm.org/doi/abs/10.1056/NEJMoa2404881

5. Bikov A, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/39626095/

6. Cazzola M, Rogliani P, Ora J, et al. Potential use of GLP-1 and GIP/GLP-1 receptor agonists for respiratory disorders. PMC Pharmaceuticals. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11728110/

7. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness. J Clin Endocrinol Metab. 2001;86(2):517-520. https://pubmed.ncbi.nlm.nih.gov/11238505/

8. Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis. Endocr Connect. 2017;6(7):437-445. https://pmc.ncbi.nlm.nih.gov/articles/PMC5574283/

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. The information presented here should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health, please seek immediate medical attention.